NASDAQ panel grants Generex's request for continued listing

Download PDF Copy

Reviewed

Generex Biotechnology CorporationJul 15 2010

Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced its receipt of a decision by the NASDAQ Listing Qualifications Panel, which granted the Company's request for continued listing of the Company's common stock on The NASDAQ Stock Market on an interim basis, subject to certain conditions subsequent which are described in the Form 8-K Current Report filed by the Company with the Securities and Exchange Commission on EDGAR (www.sec.gov) earlier today.

"I am pleased to see that the Panel recognized the opportunities available to the Company through prospective business events and gave us the opportunity to remain listed on The NASDAQ Stock Market," said Anna Gluskin, the Company's President & Chief Executive Officer. "We are looking forward to our upcoming annual meeting of the Generex stockholders and the prospect of an exciting and positive year ahead."

Source:

Generex Biotechnology Corporation

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

Bottlebrush particles deliver large range of chemotherapy drugs directly to tumor cells

New method greatly improves the precision of genome editing

QuEChERS method enhances detection of harmful compounds in food

Revolutionizing therapeutic protein design with synthetic biology

AI breakthrough designs peptide drugs to target previously untreatable proteins

Aptamer Group introduces novel biomarker discovery service

Dementia-like protein clumping found in early pancreatic cancer cells

Unlocking hidden soil microbes for new antibiotics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.